Aaron Seth Kesselheim, M.D.
This page shows the publications co-authored by Aaron Kesselheim and Sebastian Schneeweiss.
Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clin Pharmacol Ther. 2020 08; 108(2):350-357.
Multimodal Analysis of FDA Drug Safety Communications: Lessons from Zolpidem. Drug Saf. 2019 11; 42(11):1287-1295.
Desmopressin and the risk of hyponatremia: A population-based cohort study. PLoS Med. 2019 10; 16(10):e1002930.
Use of Health Care Databases to Support Supplemental Indications of Approved Medications. JAMA Intern Med. 2018 01 01; 178(1):55-63.
Changes in prescribing and healthcare resource utilization after FDA Drug Safety Communications involving zolpidem-containing medications. Pharmacoepidemiol Drug Saf. 2017 Jun; 26(6):712-721.
Erratum to: Methodological Approaches to Evaluate the Impact of FDA Drug Safety Communications. Drug Saf. 2015 Sep; 38(9):845.
Methodological approaches to evaluate the impact of FDA drug safety communications. Drug Saf. 2015 Jun; 38(6):565-75.
Ensuring patient privacy in data sharing for postapproval research. N Engl J Med. 2014 Oct 23; 371(17):1644-9.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.